Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting

Basit Öğe Kaydı
dc.contributor.authorDinleyici, Ener Cagri
dc.contributor.authorDalgic, Nazan
dc.contributor.authorGuven, Sirin
dc.contributor.authorMetin, Ozge
dc.contributor.authorYasa, Olcay
dc.contributor.authorKurugol, Zafer
dc.contributor.authorTurel, Ozden
dc.contributor.authorTanir, Gonul
dc.contributor.authorYazar, Ahmet Sami
dc.contributor.authorArica, Vefik
dc.contributor.authorSancar, Mesut
dc.contributor.authorKarbuz, Adem
dc.contributor.authorEren, Makbule
dc.contributor.authorOzen, Metehan
dc.contributor.authorKara, Ates
dc.contributor.authorVandenplas, Yvan
dc.date.accessioned2019-10-27T22:26:38Z
dc.date.available2019-10-27T22:26:38Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: Two randomized controlled clinical trials have shown that Lactobacillus (L) reuteri DSM 17938 reduces the duration of diarrhea in children hospitalized due to acute infectious diarrhea. This was the first trial evaluating the efficacy of L. reuteri DSM 17938 in outpatient children with acute infectious diarrhea. Methods: This was a multicenter, randomized, single-blinded, case control clinical trial in children with acute watery diarrhea. A total of 64 children who presented at outpatient clinics were enrolled. The probiotic group received 1 x 10(8) CFU L. reuteri DSM 17938 for five days in addition to oral rehydration solution (ORS) and the second group was treated with ORS only. The primary endpoint was the duration of diarrhea (in hours). The secondary endpoint was the number of children with diarrhea at each day of the five days of intervention. Adverse events were also recorded. Results: The mean duration of diarrhea was significantly reduced in the L. reuteri group compared to the control group (approximately 15h, 60.4 +/- 24.5 h [95% CI: 51.0-69.7h] vs. 74.3 +/- 15.3 h [95% CI: 68.7-79.9h], p < 0.05). The percentage of children with diarrhea was lower in the L. reuteri group (13/29; 44.8%) after 48 h than the control group (27/31; 87%; RR: 0.51; 95% CI: 0.34-0.79, p< 0.01). From the 72nd hour of intervention onwards, there was no difference between the two groups in the percentage of children with diarrhea. No adverse effects related to L. reuteri were noted. Conclusion: L. reuteri DSM 17938 is effective, safe, and well-tolerated in outpatient children with acute infectious diarrhea. (C) 2015 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. All rights reserved.en_US
dc.identifier.doi10.1016/j.jped.2014.10.009en_US
dc.identifier.endpage396en_US
dc.identifier.issn0021-7557
dc.identifier.issn1678-4782
dc.identifier.issue4en_US
dc.identifier.pmid25986615en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage392en_US
dc.identifier.urihttps://doi.org/10.1016/j.jped.2014.10.009
dc.identifier.urihttps://hdl.handle.net/11454/50329
dc.identifier.volume91en_US
dc.identifier.wosWOS:000359958400014en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSoc Brasil Pediatriaen_US
dc.relation.ispartofJornal De Pediatriaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLactobacillus reuteri DSM 17938en_US
dc.subjectDiarrheaen_US
dc.subjectChildrenen_US
dc.subjectProbioticen_US
dc.subjectAmbulatory careen_US
dc.titleLactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient settingen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu